Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Male breast cancer: a disease distinct from female breast cancer.

Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F.

Breast Cancer Res Treat. 2018 Sep 28. doi: 10.1007/s10549-018-4921-9. [Epub ahead of print] Review.

PMID:
30267249
2.

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, Baselga J.

Cancer Cell. 2018 Sep 10;34(3):427-438.e6. doi: 10.1016/j.ccell.2018.08.008.

PMID:
30205045
3.

Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.

Cadoo KA, Kaufman PA, Seidman AD, Chang C, Xing D, Traina TA.

Clin Breast Cancer. 2018 Apr 7. pii: S1526-8209(17)30768-1. doi: 10.1016/j.clbc.2018.04.001. [Epub ahead of print]

PMID:
29895438
4.

Reply to K.S. Shohdy et al.

Traina TA, Cortes J.

J Clin Oncol. 2018 Aug 10;36(23):2458-2459. doi: 10.1200/JCO.2018.78.8349. Epub 2018 May 30. No abstract available.

PMID:
29847296
5.

Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.

Bardia A, Gucalp A, DaCosta N, Gabrail N, Danso M, Ali H, Blackwell KL, Carey LA, Eisner JR, Baskin-Bey ES, Traina TA.

Breast Cancer Res Treat. 2018 May 9. doi: 10.1007/s10549-018-4813-z. [Epub ahead of print]

PMID:
29744674
6.

First international TNBC conference meeting report.

Rida P, Ogden A, Ellis IO, Varga Z, Wolff AC, Traina TA, Hatzis C, Palmer JR, Ambrosone CB, Lehmann BD, Nanda R, Montgomery Rice V, Brawley OW, Torres MA, Rakha E, Aneja R.

Breast Cancer Res Treat. 2018 Jun;169(3):407-412. doi: 10.1007/s10549-018-4692-3. Epub 2018 Feb 8. Review.

PMID:
29417299
7.

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J.

J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26.

PMID:
29373071
8.

Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG).

Abraham J, Caldera H, Coleman R, Elias A, Goetz MP, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Rugo H, Schwartzberg L, Traina T, Vogel C.

Breast Cancer Res Treat. 2018 May;169(1):1-7. doi: 10.1007/s10549-018-4662-9. Epub 2018 Jan 19. Review.

9.

OncoKB: A Precision Oncology Knowledge Base.

Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N.

JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00011. Epub 2017 May 16.

10.

The Androgen Receptor: Is It a Promising Target?

Gucalp A, Traina TA.

Ann Surg Oncol. 2017 Oct;24(10):2876-2880. doi: 10.1245/s10434-017-5961-9. Epub 2017 Aug 1. Review.

PMID:
28766215
11.

Androgen receptor-positive, triple-negative breast cancer.

Gucalp A, Traina TA.

Cancer. 2017 May 15;123(10):1686-1688. doi: 10.1002/cncr.30683. Epub 2017 Apr 12. No abstract available.

12.

A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer.

Schwartzberg LS, Yardley DA, Elias AD, Patel M, LoRusso P, Burris HA, Gucalp A, Peterson AC, Blaney ME, Steinberg JL, Gibbons JA, Traina TA.

Clin Cancer Res. 2017 Aug 1;23(15):4046-4054. doi: 10.1158/1078-0432.CCR-16-2339. Epub 2017 Mar 9.

13.

Targeting the androgen receptor in triple-negative breast cancer.

Gucalp A, Traina TA.

Curr Probl Cancer. 2016 Mar - Aug;40(2-4):141-150. doi: 10.1016/j.currproblcancer.2016.09.004. Epub 2016 Sep 20. Review.

14.

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.

Smyth LM, Iyengar NM, Chen MF, Popper SM, Patil S, Wasserheit-Lieblich C, Argolo DF, Singh JC, Chandarlapaty S, Sugarman SM, Comen EA, Drullinsky PR, Traina TA, Troso-Sandoval T, Baselga J, Norton L, Hudis CA, Dang CT.

Breast Cancer Res Treat. 2016 Jul;158(1):91-97. doi: 10.1007/s10549-016-3851-7. Epub 2016 Jun 15.

15.

Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review.

Cadoo KA, Gajria D, Suh E, Patil S, Theodoulou M, Norton L, Hudis CA, Traina TA.

NPJ Breast Cancer. 2016 Mar 30;2:16006. doi: 10.1038/npjbcancer.2016.6. eCollection 2016.

16.

A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.

Iyengar NM, Fornier MN, Sugarman SM, Theodoulou M, Troso-Sandoval TA, D'Andrea GM, Drullinsky PR, Gajria D, Goldfarb SB, Comen EA, Lake DE, Modi S, Traina TA, Lacouture ME, Chen MF, Patil S, Baselga J, Norton L, Hudis CA, Dang CT.

Clin Breast Cancer. 2016 Apr;16(2):87-94. doi: 10.1016/j.clbc.2015.09.009. Epub 2015 Sep 25.

17.

Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.

Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA, Marques RJ.

JAMA Oncol. 2016 Jan;2(1):65-73. doi: 10.1001/jamaoncol.2015.3251. Review.

18.

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW.

J Clin Oncol. 2015 Jun 10;33(17):1902-9. doi: 10.1200/JCO.2014.57.6660. Epub 2015 Apr 6.

19.

TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.

Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ Jr, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC; Translational Breast Cancer Research Consortium (TBCRC).

Clin Cancer Res. 2015 Jun 15;21(12):2722-9. doi: 10.1158/1078-0432.CCR-14-2780. Epub 2015 Mar 16.

20.

Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.

Paoletti C, Li Y, Muñiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson VG, Irvin WJ Jr, Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero-Torres A, Hayes DF; Translational Breast Cancer Research Consortium (TBCRC).

Clin Cancer Res. 2015 Jun 15;21(12):2771-9. doi: 10.1158/1078-0432.CCR-14-2781. Epub 2015 Mar 16.

21.

Targeting the androgen receptor in prostate and breast cancer: several new agents in development.

Proverbs-Singh T, Feldman JL, Morris MJ, Autio KA, Traina TA.

Endocr Relat Cancer. 2015 Jun;22(3):R87-R106. doi: 10.1530/ERC-14-0543. Epub 2015 Feb 26. Review.

22.

Palbociclib: an evidence-based review of its potential in the treatment of breast cancer.

Cadoo KA, Gucalp A, Traina TA.

Breast Cancer (Dove Med Press). 2014 Aug 4;6:123-33. doi: 10.2147/BCTT.S46725. eCollection 2014. Review.

23.

Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity?

Mandelblatt JS, Stern RA, Luta G, McGuckin M, Clapp JD, Hurria A, Jacobsen PB, Faul LA, Isaacs C, Denduluri N, Gavett B, Traina TA, Johnson P, Silliman RA, Turner RS, Howard D, Van Meter JW, Saykin A, Ahles T.

J Clin Oncol. 2014 Jun 20;32(18):1909-18. doi: 10.1200/JCO.2013.54.2050. Epub 2014 May 19.

24.

Tolerability of chemotherapy in HIV-infected women with breast cancer: are there prognostic implications?

Parameswaran L, Taur Y, Shah MK, Traina TA, Seo SK.

AIDS Patient Care STDS. 2014 Jul;28(7):358-64. doi: 10.1089/apc.2013.0370. Epub 2014 May 19.

PMID:
24839993
25.

Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?

Mandelblatt JS, Hurria A, McDonald BC, Saykin AJ, Stern RA, VanMeter JW, McGuckin M, Traina T, Denduluri N, Turner S, Howard D, Jacobsen PB, Ahles T; Thinking and Living With Cancer Study.

Semin Oncol. 2013 Dec;40(6):709-25. doi: 10.1053/j.seminoncol.2013.09.006. Review.

26.

Advances in molecular and clinical subtyping of breast cancer and their implications for therapy.

Cadoo KA, Traina TA, King TA.

Surg Oncol Clin N Am. 2013 Oct;22(4):823-40. doi: 10.1016/j.soc.2013.06.006. Epub 2013 Jul 27. Review.

PMID:
24012401
27.

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.

Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA; Translational Breast Cancer Research Consortium (TBCRC 011).

Clin Cancer Res. 2013 Oct 1;19(19):5505-12. doi: 10.1158/1078-0432.CCR-12-3327. Epub 2013 Aug 21.

28.

The role of the androgen receptor in triple-negative breast cancer.

Shah PD, Gucalp A, Traina TA.

Womens Health (Lond). 2013 Jul;9(4):351-60. doi: 10.2217/whe.13.33. Review.

PMID:
23826776
29.

Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer.

Zumsteg ZS, Morrow M, Arnold B, Zheng J, Zhang Z, Robson M, Traina T, McCormick B, Powell S, Ho AY.

Ann Surg Oncol. 2013 Oct;20(11):3469-76. doi: 10.1245/s10434-013-3011-9. Epub 2013 May 19. Review.

30.

Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis.

Perez CA, Zumsteg ZS, Gupta G, Morrow M, Arnold B, Patil SM, Traina TA, Robson ME, Wen YH, McCormick B, Powell SN, Ho AY.

Breast Cancer Res Treat. 2013 Jun;139(2):497-506. doi: 10.1007/s10549-013-2550-x. Epub 2013 May 5.

PMID:
23645006
31.

Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy.

Ho AY, Gupta G, King TA, Perez CA, Patil SM, Rogers KH, Wen YH, Brogi E, Morrow M, Hudis CA, Traina T, McCormick B, Powell SN, Robson ME.

Cancer. 2012 Oct 15;118(20):4944-52. doi: 10.1002/cncr.27480. Epub 2012 Mar 5.

32.

Triple-negative breast cancer: adjuvant therapeutic options.

Gucalp A, Traina TA.

Chemother Res Pract. 2011;2011:696208. doi: 10.1155/2011/696208. Epub 2011 Jun 21.

33.

Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.

Gajria D, Gonzalez J, Feigin K, Patil S, Chen C, Theodoulou M, Drullinsky P, D'Andrea G, Lake D, Norton L, Hudis CA, Traina TA.

Breast Cancer Res Treat. 2012 Jan;131(1):111-6. doi: 10.1007/s10549-011-1749-y. Epub 2011 Sep 4.

PMID:
21898114
34.

Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.

Gucalp A, Sparano JA, Caravelli J, Santamauro J, Patil S, Abbruzzi A, Pellegrino C, Bromberg J, Dang C, Theodoulou M, Massague J, Norton L, Hudis C, Traina TA.

Clin Breast Cancer. 2011 Oct;11(5):306-11. doi: 10.1016/j.clbc.2011.03.021. Epub 2011 May 3.

35.

Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.

Gajria D, Feigin K, Tan LK, Patil S, Geneus S, Theodoulou M, Norton L, Hudis CA, Traina TA.

Cancer. 2011 Sep 15;117(18):4125-31. doi: 10.1002/cncr.25992. Epub 2011 Mar 8.

36.

A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.

McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN.

Clin Cancer Res. 2011 May 15;17(10):3398-407. doi: 10.1158/1078-0432.CCR-10-1969. Epub 2011 Feb 24.

37.

Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.

Drullinsky P, Sugarman SM, Fornier MN, D'Andrea G, Gilewski T, Lake D, Traina T, Wasserheit-Lieblich C, Sklarin N, Atieh-Graham D, Mills N, Troso-Sandoval T, Seidman AD, Yuan J, Patel H, Patil S, Norton L, Hudis C.

Clin Breast Cancer. 2010 Dec 1;10(6):440-4. doi: 10.3816/CBC.2010.n.057.

38.

The clinical impact and outcomes of immunohistochemistry-only metastasis in breast cancer.

Pugliese M, Stempel M, Patil S, Hsu M, Ho A, Traina T, Morrow M, Cody H 3rd, Gemignani ML.

Am J Surg. 2010 Sep;200(3):368-73. doi: 10.1016/j.amjsurg.2009.10.016.

PMID:
20800716
39.

Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.

Conlin AK, Seidman AD, Bach A, Lake D, Dickler M, D'Andrea G, Traina T, Danso M, Brufsky AM, Saleh M, Clawson A, Hudis CA.

Clin Breast Cancer. 2010 Aug 1;10(4):281-7. doi: 10.3816/CBC.2010.n.036.

40.

Determinants of outcome in elderly patients with positive sentinel lymph nodes.

Karam AK, Hsu M, Patil S, Stempel M, Traina TA, Ho AY, Cody HS, Morrow M, Gemignani ML.

Am J Surg. 2011 Jun;201(6):734-40. doi: 10.1016/j.amjsurg.2010.02.005. Epub 2010 Jul 8.

PMID:
20619395
41.

Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling.

Traina TA, Dugan U, Higgins B, Kolinsky K, Theodoulou M, Hudis CA, Norton L.

Breast Dis. 2010;31(1):7-18. doi: 10.3233/BD-2009-0290.

42.

Capecitabine dosing is not yet optimized for breast cancer.

Hudis C, Traina T, Norton L.

Ann Oncol. 2010 Nov;21(11):2291; author reply 2291-2. doi: 10.1093/annonc/mdq264. Epub 2010 May 25. No abstract available.

PMID:
20501505
43.

Triple-negative breast cancer: role of the androgen receptor.

Gucalp A, Traina TA.

Cancer J. 2010 Jan-Feb;16(1):62-5. doi: 10.1097/PPO.0b013e3181ce4ae1. Review. Erratum in: Cancer J. 2010 Nov-Dec;16(6):643.

PMID:
20164692
44.

Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer.

Pugliese MS, Karam AK, Hsu M, Stempel MM, Patil SM, Ho AY, Traina TA, Van Zee KJ, Cody HS 3rd, Morrow M, Gemignani ML.

Ann Surg Oncol. 2010 Apr;17(4):1063-8. doi: 10.1245/s10434-009-0834-5. Epub 2009 Dec 22.

PMID:
20033325
45.

Bevacizumab for advanced breast cancer.

Goldfarb SB, Traina TA, Dickler MN.

Womens Health (Lond). 2010 Jan;6(1):17-25. doi: 10.2217/whe.09.71. Review.

PMID:
20001867
46.

Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.

Morris PG, Dickler M, McArthur HL, Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT.

J Clin Oncol. 2009 Dec 20;27(36):6117-23. doi: 10.1200/JCO.2008.20.2952. Epub 2009 Nov 9.

47.

Targeting insulin-like growth factor type 1 receptor in cancer therapy.

Atzori F, Traina TA, Ionta MT, Massidda B.

Target Oncol. 2009 Dec;4(4):255-66. doi: 10.1007/s11523-009-0123-z. Epub 2009 Oct 30. Review.

PMID:
19876700
48.

Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.

Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, Park JW, Geneus S, Paulson M, Grothusen J, Seidman AD, Fornier M, Lake D, Dang C, Robson M, Theodoulou M, Flombaum CD, Norton L, Hudis CA, Dickler MN.

J Clin Oncol. 2010 Feb 1;28(4):628-33. doi: 10.1200/JCO.2009.21.8784. Epub 2009 Oct 19.

49.

PIK3CA mutation associates with improved outcome in breast cancer.

Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME.

Clin Cancer Res. 2009 Aug 15;15(16):5049-59. doi: 10.1158/1078-0432.CCR-09-0632. Epub 2009 Aug 11.

50.

Bevacizumab in the treatment of metastatic breast cancer.

Traina TA.

Oncology (Williston Park). 2009 Apr 15;23(4):327-32. Review.

Supplemental Content

Loading ...
Support Center